lorecivivint (SM04690) / Biosplice Therap, Samil Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lorecivivint (SM04690) / Biosplice Therap, Samil Pharma
NCT02536833: A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects

Completed
2
455
US
SM04690, Placebo
Biosplice Therapeutics, Inc.
Osteoarthritis
04/17
04/17
NCT03122860: A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Completed
2
700
US
SM04690, Placebo, Sham
Biosplice Therapeutics, Inc.
Knee Osteoarthritis
04/18
04/18
NCT03706521: A Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Terminated
2
13
US
SM04690, lorecivivint
Biosplice Therapeutics, Inc.
Knee Osteoarthritis
07/20
12/20
NCT03727022: A Study Evaluating the Safety, Tolerability and Efficacy of Two Injections of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

Completed
2
102
US
Placebo, SM04690
Biosplice Therapeutics, Inc.
Knee Osteoarthritis
09/20
08/21

Download Options